Skip to main content
    6

    60 Degrees Pharmaceuticals, Inc. Common Stock (SXTP)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.49
    -0.02 (-4.60%)

    Market Cap: $1.82M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    60 Degrees Pharmaceuticals, Inc. Common Stock (SXTP) Earnings: Report Dates and Results

    Updated Aug 14, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    In the quarter ended Jun 30, 2026, 60 Degrees Pharmaceuticals, Inc. Common Stock reported EPS of -$0.90, below the -$0.74 estimate. It beat the EPS estimate in 2 of the 8 most recent quarters that had an estimate.

    Earnings

    Performance (10Y)

    Beat Rate
    27%(3/11)
    Avg Surprise
    -33.35%

    Upcoming Estimates

    Report date not yet scheduledPeriod ending Dec 31, 2026
    EPS Consensus-$0.80
    Range-$0.87 - -$0.70
    4 analysts
    Revenue Consensus
    $311.10K
    Range$294.00K - $325.50K
    4 analysts

    Next Report

    SXTP's report for the quarter ending Dec 31, 2026 is not on the earnings calendar yet.

    Earnings History

    Of the 11 quarters below that had an estimate, SXTP beat 3 and missed 8. Revenue for the quarter ended Jun 30, 2026 was $207898, down 32.5% from $307871 a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Jun 30, 2026-$0.90-$0.74N/A-21.62%MissN/A10 up, 1 downAug 14, 2026$207898
    Mar 31, 2026-$1.21-$0.99-$0.99 - -$0.99-22.65%MissN/A11 up, 0 downMay 15, 2026$162092
    Dec 31, 2025-$8.17-$8.00-$8.00 - -$8.00-2.12%MissN/A10 up, 1 downMar 26, 2026$409110
    Sep 30, 2025-$2.53-$1.84-$1.84 - -$1.84-37.50%MissN/A11 up, 0 downNov 13, 2025$528562
    Jun 30, 2025-$4.33-$4.96-$4.96 - -$4.96+12.70%BeatN/A11 up, 0 downAug 13, 2025$307871
    Mar 31, 2025-$1.56-$1.31N/A-19.08%MissN/A11 up, 0 downMay 15, 2025$256283
    Dec 31, 2024-$2.16-$0.18N/AN/AN/AN/A11 up, 0 downMar 27, 2025$302588
    Sep 30, 2024-$17.35-$17.40-$18.60 - -$16.20+0.29%Beat-109.4%21 up, 0 downNov 14, 2024$148111
    Jun 30, 2024-$84.60-$33.60-$46.94 - -$20.17-151.79%MissN/A21 up, 0 downAug 14, 2024$124972
    Mar 31, 2024-$31.54-$52.80N/A+40.27%BeatN/A20 up, 0 downApr 1, 2024$105674
    Dec 31, 2023-$0.35-$0.14-$0.27 - -$0.14-146.43%MissN/A20 up, 0 downFeb 28, 2024$118273
    Sep 30, 2023$184.80$228.00-$62.42 - $518.61-18.95%MissN/A20 up, 0 downNov 20, 2023$51188
    Jun 30, 2023-$1.10N/AN/AN/AN/AN/AN/AN/AAug 25, 2023$62648
    Last 13 quarters

    Estimates made before a stock split are shown on the same share basis as the reported EPS.

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$16.59, after -$135.65 the year before. It was $183.36 for the year ended Dec 31, 2023, the oldest of the 3 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$16.59N/A
    Dec 31, 2024-$135.65-174.0%
    Dec 31, 2023$183.36N/A

    Frequently Asked Questions About SXTP

    Did SXTP beat earnings estimates last quarter?

    No. 60 Degrees Pharmaceuticals, Inc. Common Stock reported EPS of -$0.90 for the quarter ended Jun 30, 2026, below the -$0.74 estimate by 21.62%.

    What EPS do analysts expect from SXTP next quarter?

    The consensus EPS estimate for 60 Degrees Pharmaceuticals, Inc. Common Stock for the quarter ending Dec 31, 2026 is -$0.80 from 4 analysts, with estimates from -$0.87 to -$0.70.

    How often does SXTP beat earnings estimates?

    60 Degrees Pharmaceuticals, Inc. Common Stock beat the EPS estimate in 2 of the 8 most recent quarters that had an estimate, with an average surprise of -30.22%.